Ojeok-san enhances platinum sensitivity in ovarian cancer by regulating adipocyte paracrine IGF1 secretion

Adipocyte. 2024 Dec;13(1):2282566. doi: 10.1080/21623945.2023.2282566. Epub 2023 Nov 22.

Abstract

Background: Platinum is a commonly used drug for ovarian cancer (OvCa) treatment, but drug resistance limits its clinical application. This study intended to delineate the effects of adipocytes on platinum resistance in OvCa.

Methods: OvCa cells were maintained in the adipocyte-conditioned medium. Cell viability and apoptosis were detected by CCK-8 and flow cytometry, separately. Proliferation and apoptosis-related protein expression were assayed by western blot. The IC50 values of cisplatin and carboplatin were determined using CCK-8. IGF1 secretion and expression were assayed via ELISA and western blot, respectively. A xenograft model was established, and pathological changes were detected by H&E staining. Proliferation and apoptosis-associated protein expression was assessed via IHC.

Results: Adipocytes promoted the viability and repressed cell apoptosis in OvCa, as well as enhancing platinum resistance, while the addition of IGF-1 R inhibitor reversed the effects of adipocytes on proliferation, apoptosis, and drug resistance of OvCa cells. Treatment with different concentrations of Ojeok-san (OJS) inhibited the adipocyte-induced platinum resistance in OvCa cells by suppressing IGF1. The combined treatment of OJS and cisplatin significantly inhibited tumour growth in vivo with good mouse tolerance.

Conclusion: In summary, OJS inhibited OvCa proliferation and platinum resistance by suppressing adipocyte paracrine IGF1 secretion.

Keywords: IGF1; OJS; Ovarian cancer; adipocyte; platinum.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adipocytes / metabolism
  • Animals
  • Cisplatin* / metabolism
  • Cisplatin* / pharmacology
  • Cisplatin* / therapeutic use
  • Drug Resistance, Neoplasm
  • Female
  • Humans
  • Insulin-Like Growth Factor I / metabolism
  • Mice
  • Ovarian Neoplasms* / drug therapy
  • Ovarian Neoplasms* / metabolism
  • Ovarian Neoplasms* / pathology
  • Sincalide / metabolism
  • Sincalide / pharmacology
  • Sincalide / therapeutic use

Substances

  • Cisplatin
  • ojeok-san
  • Insulin-Like Growth Factor I
  • Sincalide
  • IGF1 protein, human

Grants and funding

This work was supported by Zhejiang Provincial Natural Science Foundation of China (LQ22H160029).